Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
94.76 BRL | +20.88% |
|
-2.32% | +39.13% |
07-03 | Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval | MT |
07-03 | Sanofi obtains EU approval for Dupixent | RE |
- Stock Market
- Equities
- REGN Stock
- REGN34 Stock
- News Regeneron Pharmaceuticals, Inc.
- MarketScreener Strategies